Selected article for: "adaptive immunity and adoptive transfer"

Author: Li, Dan; Li, Xue; Zhou, Wei-Lin; Huang, Yong; Liang, Xiao; Jiang, Lin; Yang, Xiao; Sun, Jie; Li, Zonghai; Han, Wei-Dong; Wang, Wei
Title: Genetically engineered T cells for cancer immunotherapy
  • Cord-id: zzc6tycb
  • Document date: 2019_9_20
  • ID: zzc6tycb
    Snippet: T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs ha
    Document: T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.

    Search related documents:
    Co phrase search for related documents
    • activation motif and acute phase response: 1
    • activation signal and acute phase: 1, 2
    • activation signal and adaptive immunity: 1, 2, 3
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and administration route: 1, 2
    • acute phase response and adaptive immunity: 1
    • adaptive immunity and administration route: 1, 2